ThomasEBuekersMD

Obstetrics & Gynecology • Southfield, MI

Gynecologic Oncology

Chairman, Obstetrics and Gynecology Ascension Providence Hospitals Southfield, Michigan

Join to view full profile

Dr. Buekers is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Buekers' full profile

Already have an account?

Office
16001 W 9 Mile Rd
Southfield, MI 48075

Summary

Dr. Thomas Buekers is an obstetrician/gynecologist in Detroit, MI and is affiliated with multiple hospitals in the area, including Henry Ford Hospital, Henry Ford Macomb Hospitals, Henry Ford West Bloomfield Hospital, and Henry Ford Wyandotte Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 27 years. He specializes in gynecologic oncology and is experienced in ovarian neoplasms, uterine neoplasms, vulvar cancers and complex Gynecologic surgeries.

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 1996 - 2000
Corewell Health East Beaumont (Royal Oak)Residency, Obstetrics and Gynecology, 1992 - 1996
Wayne State University School of MedicineClass of 1992, MD
University of DetroitBS, Chemistry, Magna cum laude, 1984 - 1988

Certifications & Licensure

MI State Medical License 1994 - 2026
IA State Medical License 1996 - 2010
VA State Medical License 2000 - 2004
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2011 Aug 15
Active, not recruiting
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

47 citations
Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach
Susan K. Lutgendorf, Elizabeth Mullen-Houser, Daniel W. Russell, Koen DeGeest, Geraldine M. Jacobson
Brain, Behavior, and Immunity. 2010-11-01
103 citations
Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells
Sajad Ahmad Dar, Jasdeep Chhina, Ismail Mert, Dhananjay Chitale, Thomas E. Buekers
Scientific Reports. 2017-08-18
129 citations
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Richard E. Buller, Ingo B Runnebaum, Beth Y. Karlan, Jo Ann Horowitz, Mark S. Shahin
Cancer Gene Therapy. 2002-07-01

Other

Rate of Urologic Injury with Robotic Hysterectomy
Petersen SS, Doe S, Rubinfeld I, Davydova Y, Buekers T, Sangha R.
7/2018
Definitive radiation therapy for cervical cancer: Non-white race and public insurance are risk factors for delayed completion, a pilot study
Petersen SS, Doe S, Buekers T.
2018
A Comparative Study of Clinical Characteristics and Preoperative Findings of Different Sarcoma Types
Aoun J, Baum S, Buekers T, Schiff L, Eisenstein D, Tsafrir Z, Stovall D.
11/2015
A Comparative Study of the Methods of Diagnosis and Outcomes of Different Uterine Sarcoma Types
Aoun J, Baum S, Buekers T, Schiff L, Eisenstein D, Tsafrir Z, Stovall D.
11/2015
A Comparative Study of Preoperative Findings and Outcomes in Pre-Menopausal and Post-Menopausal Women With Leiomyosarcoma
Aoun J, Baum S, Buekers T, Schiff L, Theoharis E, Tsafrir Z.
11/2015
Endometrial carcinoma in the baby boomer generation. Tumor characteristics and clinical outcome
Elshaikh MA, Cattaneo R, 2nd, Shah M, Patel S, Mahan M, Buekers T, Siddiqui F.
2/2013
Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma
Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE.
12/2001
Ovarian function after surgical treatment for cervical cancer
Buekers TE, Anderson B, Sorosky JI, Buller RE.
1/2001
Asymptomatic lung carcinoma presenting with a large vulvar lesion.
Cooper BC, Buekers TE, Flynn CM, Sorosky JI, Buller RE.
1/2001
Docetaxel extravasation causing significant delayed tissue injury
Raley J, Geisler JP, Buekers TE, Sorosky JI.
8/2000
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer
Buekers TE, Lallas TA, Buller RE.
3/2000
Hematogenous skin metastases from cervical cancer at primary presentation
Pertzborn S, Buekers TE, Sood AK.
3/2000
RESPONSE: Re: Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer
Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS.
9/1/1999
BRCA1 mutations in familial ovarian cancer
Lallas TA, Buekers TE, Buller RE.
8/1999
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer
Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS.
2/17/1999
A case of severe hidradenitis suppurativa contributing to a death and a review of the literature
Groginsky EM, Olson JK, Lallas TA, Buekers TE, Potts S, Sorosky JI.
1/1999
Polyarteritis nodosa of the vagina mimicking vaginal carcinoma
Buekers TE, Bonsib SM, Sorosky JI.
10/1998
A novel technique for gynecologic oncology surgery in the presence of abdominal wall mesh prosthesis
Buekers TE, Sorosky JI, Buller RE.
7/1998
Chemotherapy in pregnancy
Buekers TE, Lallas TA.
6/1998
The use of chemotherapeutic agents during pregnancy
Sorosky JI, Sood AK, Buekers TE.
9/1997
Join now to see all

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow